Morphine News and Research

Latest Morphine News and Research

Caltech researchers devise new method to make complex molecules

A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.

12 Jan 2012

Powerful painkiller on its way to the market: Experts worry about addiction woes

Drug makers are on their way to a pure, more powerful version of the nation’s second most-abused medicine, which has addiction experts worried that it could spur a new wave of abuse. The new pills contain the highly addictive painkiller hydrocodone, packing up to 10 times the amount of the drug as existing medications such as Vicodin.

28 Dec 2011

Actavis enters LOI with QRxPharma to commercialize MoxDuo IR in the U.S.

Actavis Group, the international generic pharmaceuticals company, today announced that its US subsidiary, Actavis Inc, has entered into a binding letter of intent (LOI) with QRxPharma Limited to commercialize MoxDuo IR in the United States.

21 Dec 2011

Study shows how mothering can strengthen offspring's immune system in brain

An attentive, nurturing mother may be able to help her children better resist the temptations of drug use later in life, according to a study involving the University of Adelaide.

8 Dec 2011

Combination of cannabinoids and opiates could help reduce chronic pain

A UCSF study suggests patients with chronic pain may experience greater relief if their doctors add cannabinoids - the main ingredient in cannabis or medical marijuana - to an opiates-only treatment. The findings, from a small-scale study, also suggest that a combined therapy could result in reduced opiate dosages.

7 Dec 2011

Evaluating passive harms requires more thought, finds study

People typically say they are invoking an ethical principle when they judge acts that cause harm more harshly than willful inaction that allows that same harm to occur. That difference is even codified in criminal law.

3 Dec 2011

Anesthesia drug shortages can have devastating impact on patient care

The United States is facing ongoing shortages of several critical anesthesia medications—shortages with potentially serious effects on patient care and safety, according to a special article in the December issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

24 Nov 2011

Research shows how the bite of a small Texas snake causes extreme pain

Examining venom from a variety of poisonous snakes, a group of researchers at the University of California, San Francisco has discovered why the bite of one small black, yellow and red serpent called the Texas coral snake can be so painful.

17 Nov 2011

Scientists discover promising approaches for treatment of pain

Scientists are discovering promising approaches to treating pain, one of the most common and debilitating neurological complaints, according to research released today at Neuroscience 2011, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Nov 2011

Older patients less likely to receive pain medication in hospital EDs

A new study finds that people 75 years old or older are less likely to receive any pain medication in hospital emergency departments than middle aged people - those between 35 and 54 years old.

13 Nov 2011

Actavis begins shipping Morphine Sulfate Extended-Release Capsules

Actavis, an international generic pharmaceutical company, today announced that it has begun shipping Morphine Sulfate Extended-Release Capsules, USP CII, an authorized generic of KADIAN.

11 Nov 2011

Watson receives FDA approval for generic Kadian ANDA

Watson Pharmaceuticals, Inc. today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian.

11 Nov 2011

IRCM peptide chemist listed as inventor on two U.S. patents

In 2010, after more than 10 years of basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist and Director of the Chemical Biology and Peptide research unit at the Institut de recherches cliniques de Montr-al (IRCM), and his international collaborators were the listed inventors on two U.S. patents awarded to the institute and covering different uses of a unique class of peptide compounds initially synthesized in Dr. Schiller's laboratory at the IRCM.

10 Nov 2011

QRxPharma receives FDA written acceptance for review of MoxDuo IR NDA

QRxPharma Limited announced today it received written acceptance from the United States Food and Drug Administration (FDA) for review of the MoxDuo IR New Drug Application (NDA) filed earlier this year.

9 Nov 2011

AcelRx reports revenue of $408,000 for third quarter 2011

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, reported financial results today for the third quarter and nine months ended September 30, 2011.

9 Nov 2011

QRxPharma receives date for US pain drug launch, pending approval

Australian pain-relief drug developer QRxPharma (QRX) has announced today that they have received from the US Food & Drug Adminstration.

8 Nov 2011

$Narcotic analgesics increase risk of falls and fractures among elderly$

Narcotic analgesics increase risk of falls and fractures among elderly

Falls and fractures among senior citizens have increased since rofecoxib was removed from the market in 2004, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide

Clinuvel Pharmaceuticals Limited, a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE.

3 Nov 2011

Scientists identify distinct tobacco transporter for nicotine metabolism

A team of Virginia Tech and Purdue University scientists have identified a distinct transporter used by tobacco plant cells for nicotine metabolism. The research appears in the Oct. 17 online before print issue of the Proceedings of the National Academy of Sciences (PNAS) in the article, "A tobacco nicotine uptake permease effects alkaloid metabolism."

2 Nov 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011